-- Robert Preidt
MONDAY, Nov. 25, 2013 (HealthDay News) -- The U.S. Food and Drug
Administration has approved a new drug for chronic hepatitis C
infection that some experts hope will cut down on side effects from
Hepatitis C infection triggers an inflammation of the liver that
can lead to reduced liver function, liver failure and even death
over time. According to the U.S. Centers for Disease Control and
Prevention, 3.2 million Americans -- many of them in the "baby
boomer" generation -- are infected with the hepatitis C virus.
The new drug, called Olysio (simeprevir), is approved as part of
a combination antiviral drug regimen to treat certain classes of
adult patients with hepatitis C. These include people who have
cirrhosis or other liver disease but whose liver is still
functioning, people who haven't been previously treated for their
hepatitis infection, or those whose infection has not improved
after prior treatment.
The approval of Olysio is promising, one expert said, because it
might someday free some patients from having to rely on interferon,
which can have difficult side effects.
"The approval of Olysio is the first step toward once daily interferon-free treatment of hepatitis C," said Dr. Douglas Dieterich, director of outpatient hepatology at the Icahn School of Medicine at Mount Sinai in New York City.
The FDA's approval was based on the results of six clinical
trials that evaluated Olysio in combination with peginterferon-alfa
and ribavirin, two other drugs commonly used to treat hepatitis C
The three-drug combination was effective in 80 percent of
patients who had never been treated for hepatitis C, the study
found, compared to 50 percent effectiveness in patients who got an
inactive placebo plus peginterferon-alfa and ribavirin.
The three-drug combination was also 79 percent effective in
patients who had received prior treatment but had relapsed,
compared to 37 percent effectiveness in people who got only the two
older drugs, the FDA said.
Olysio is from the protease inhibitor class of drugs, and it
works by blocking a key protein the virus needs to reproduce. It's
the third such drug approved by the FDA to treat chronic hepatitis
C infection. The other two drugs are Victrelis (boceprevir) and
Incivek (telaprevir), both approved in 2011.
Another expert was optimistic about the treatment.
Olysio "is an important new addition to the hepatitis C virus
treatment regimens, offering improved efficacy, easier
administration with once-a-day dosing and an improved side effect
profile," said Dr. David Bernstein, chief of the division of
hepatology at North Shore University Hospital in Manhasset,
The clinical trials for Olysio also found that patients with a
specific strain of the hepatitis C virus commonly found in the
United States were less likely to respond to treatment with the
drug. The drug's label therefore tells doctors to screen patients
for the presence of this strain before beginning treatment with
Olysio and to consider other treatments for patients with this
Common side effects among patients who took the three-drug combo
included sensitivity to light, itching and nausea. Some patients
had severe light sensitivity that required hospitalization.
Patients will be advised to limit their sun exposure and to use sun
protective measures when taking Olysio with peginterferon-alfa and
ribavirin, the FDA said.
Dieterich believes that patients now have more options than ever
before in treating hepatitis C infection.
The approval of Olysio "represents the first once-daily protease
inhibitor, which when used with interferon and ribavirin, has about
an 80 percent success rate in curing hepatitis C in 24 weeks," he
said. "This could be the beginning of the end for hepatitis C, if
everyone that has it gets tested and treated, as the CDC recommends
for baby boomers."
Olysio is marketed by Janssen Pharmaceuticals.
The U.S. National Institute of Allergy and Infectious Diseases
has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.